CTF1 and glomerular disorder: Administration of CT‐1 to NTS‐injected mice with severe albuminuria halted glomerular disease progression as evidenced by reduced albuminuria and sustained plasma creatinine levels and podocyte density in CT‐1 compared with saline‐treated nephropathic mice 2 weeks after the initiation of CT‐1 treatment.